Search hospitals > Minnesota > Saint Paul
Regions Hospital
Claim this profileSaint Paul, Minnesota 55101
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Recurrence
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
477 reported clinical trials
24 medical researchers
Summary
Regions Hospital is a medical facility located in Saint Paul, Minnesota. This center is recognized for care of Cancer, Breast Cancer, Recurrence, Lung Cancer, Adenocarcinoma and other specialties. Regions Hospital is involved with conducting 477 clinical trials across 604 conditions. There are 24 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
David M. KingPark Nicollet Clinic - Saint Louis Park7 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
97 reported clinical trials
159 drugs studied
Daniel M. AndersonRegions Hospital4 years of reported clinical research
Expert in Cancer
Expert in Tumors
60 reported clinical trials
108 drugs studied
Yan JiRegions Hospital1 year of reported clinical research
Expert in Cancer
Studies Breast Cancer
30 reported clinical trials
74 drugs studied
Pamala A. PawloskiPark Nicollet Clinic - Saint Louis Park5 years of reported clinical research
Studies Cancer
Studies Tumors
14 reported clinical trials
19 drugs studied
Clinical Trials running at Regions Hospital
Breast Cancer
Prostate Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Multiple Myeloma
Gastric Cancer
Rectal Cancer
Esophageal Cancer
Tumors
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Regions Hospital?
Regions Hospital is a medical facility located in Saint Paul, Minnesota. This center is recognized for care of Cancer, Breast Cancer, Recurrence, Lung Cancer, Adenocarcinoma and other specialties. Regions Hospital is involved with conducting 477 clinical trials across 604 conditions. There are 24 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Where is Regions Hospital located?
**Regions Hospital Location and Directions:**
- **Address:** 640 Jackson Street, St. Paul, MN 55101.
- **Directions:**
- From I-35E South: Exit on University Avenue, turn right on University Avenue, then left on Jackson Street.
- From I-94 East: Exit at Marion Street, turn left on Marion Street, then right on University Avenue, and right on Jackson Street.
- From I-94 West or Highway 52 North to I-94 West: Exit at 12th Street, take an immediate right on Jackson Street.
- From I-35E North: Exit on 11th Street, turn left on Jackson Street.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Regions Hospital:
- **Insurance Inquiries:** Call 651-254-1884.
- **General Financial Support:** Contact Patient Accounting Customer Service at 651-254-4791 (local) or 877-974-3600 (toll-free).
- **Financial Counselors:** Reach out at 651-254-0842 for further assistance.
- **Financial Assistance Application Questions:** Contact Patient Financial Services at 651-254-4791. The application is available online.
What insurance does Regions Hospital accept?
Regions Hospital accepts a wide range of insurance plans, including but not limited to Blue Cross and Blue Shield of Minnesota, Blue Plus, HealthPartners, Medicare, Aetna, and Affinity Medical Group. These plans often provide 100% coverage for preventive care, immunizations, eye exams, and prenatal/postnatal care. For specific coverage details and to confirm if your insurance is accepted, please contact the hospital directly or consult with your insurance provider.
What awards or recognition has Regions Hospital received?
Regions Hospital in Saint Paul, Minnesota, is a recipient of the Top 25 Environmental Excellence Award from Practice Greenhealth, marking it as a leader in environmental sustainability within healthcare. It has also earned the American Heart Association's Get With The Guidelines® Stroke Gold Plus achievement award, recognizing its adherence to core standards of stroke care with 85% or higher compliance over two years. Furthermore, the hospital extends its medical expertise to Minnesota Wild, St. Paul Saints, and Minnesota Vikings home games, providing on-site medical coverage and promoting health education.